Nestmedic (WSE:NST) Second Quarter 2024 Results
Key Financial Results
- Revenue: zł116.1k (down 24% from 2Q 2023).
- Net loss: zł1.73m (loss narrowed by 9.2% from 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Nestmedic shares are down 1.1% from a week ago.
Risk Analysis
It is worth noting though that we have found 6 warning signs for Nestmedic (4 are significant!) that you need to take into consideration.
Valuation is complex, but we're here to simplify it.
Discover if Nestmedic might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:NST
Nestmedic
Engages in the manufacture, distribution, and sale of mobile telemedical solution under the Pregnabit brand.
Moderate with worrying balance sheet.
